Macrophage inflammatory protein 1-alpha (MIP-1α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells

被引:177
作者
Lentzsch, S
Gries, M
Janz, M
Bargou, R
Dörken, B
Mapara, MY
机构
[1] Univ Berlin, Med Ctr Charite, Dept Hematol Oncol & Tumorimmunol, Robert Rossle Klin, D-13125 Berlin, Germany
[2] Humboldt Univ, Berlin, Germany
关键词
D O I
10.1182/blood-2002-08-2383
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recently, it has been demonstrated that macrophage inflammatory protein 1-alpha (MIP-1alpha) is crucially involved in the development of osteolytic bone lesions in multiple myeloma (MM). The current study was designed to determine the direct effects of MIP-1alpha on MM cells. Thus, we were able to demonstrate that MIP-1alpha acts as a potent growth, survival, and chemotactic factor in MM cells. MIP-1alpha-induced signaling involved activation of the AKT/protein kinase B (PKB) and the mitogen-activated protein kinase (MAPK) pathway. In addition, inhibition of AKT activation by phosphatidylinositol 3-kinase (PI3-K) inhibitors did not influence MAPK activation, suggesting that there is no cross talk between MIP-1alpha-dependent activation of the PI3-K/AKT and extracellular-regulated kinase (ERK) pathway. Our data suggest that besides its role in development of osteolytic bone destruction, MIP-1alpha also directly affects cell signaling pathways mediating growth, survival, and migration in MM cells and provide evidence that MIP-1alpha might play a pivotal role in the pathogenesis of MM. (C) 2003 by The American Society of Hematology.
引用
收藏
页码:3568 / 3573
页数:6
相关论文
共 25 条
  • [1] Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma
    Abe, M
    Hiura, K
    Wilde, J
    Moriyama, K
    Hashimoto, T
    Ozaki, S
    Wakatsuki, S
    Kosaka, M
    Kido, S
    Inoue, D
    Matsumoto, T
    [J]. BLOOD, 2002, 100 (06) : 2195 - 2202
  • [2] Pathogenesis and management of bone lesions in multiple myeloma
    Bataille, R
    Manolagas, SC
    Berenson, JR
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1997, 11 (02) : 349 - +
  • [3] Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma
    Bergsagel, PL
    Chesi, M
    Nardini, E
    Brents, LA
    Kirby, SL
    Kuehl, WM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (24) : 13931 - 13936
  • [4] Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism
    Chauhan, D
    Pandey, P
    Ogata, A
    Teoh, G
    Treon, S
    Urashima, M
    Kharbanda, S
    Anderson, KC
    [J]. ONCOGENE, 1997, 15 (07) : 837 - 843
  • [5] Apoptosis in multiple myeloma: Therapeutic implications
    Chauhan, D
    Anderson, KC
    [J]. APOPTOSIS, 2001, 6 (1-2) : 47 - 55
  • [6] Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease
    Choi, SJ
    Oba, Y
    Gazitt, Y
    Alsina, M
    Cruz, J
    Anderson, J
    Roodman, GD
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (12) : 1833 - 1841
  • [7] Choi SJ, 2000, BLOOD, V96, P671
  • [8] Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
    Dankbar, B
    Padró, T
    Leo, R
    Feldmann, B
    Kropff, M
    Mesters, RM
    Serve, H
    Berdel, WE
    Kienast, J
    [J]. BLOOD, 2000, 95 (08) : 2630 - 2636
  • [9] FULLER K, 1995, J IMMUNOL, V154, P6065
  • [10] Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand
    Han, JH
    Choi, SJ
    Kurihara, N
    Koide, M
    Oba, Y
    Roodman, GD
    [J]. BLOOD, 2001, 97 (11) : 3349 - 3353